Artivion, Inc. $AORT Shares Sold by Connors Investor Services Inc.

Connors Investor Services Inc. trimmed its holdings in shares of Artivion, Inc. (NYSE:AORT) by 17.9% during the third quarter, HoldingsChannel reports. The institutional investor owned 103,812 shares of the company’s stock after selling 22,589 shares during the quarter. Connors Investor Services Inc.’s holdings in Artivion were worth $4,395,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the stock. Aster Capital Management DIFC Ltd boosted its holdings in Artivion by 402.3% in the 3rd quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock worth $27,000 after acquiring an additional 519 shares during the period. Caitong International Asset Management Co. Ltd bought a new stake in shares of Artivion in the third quarter worth $27,000. Smartleaf Asset Management LLC increased its stake in shares of Artivion by 47.7% in the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock worth $52,000 after buying an additional 538 shares during the last quarter. State of Wyoming acquired a new stake in Artivion in the third quarter valued at $80,000. Finally, Quadrant Capital Group LLC acquired a new stake in Artivion in the third quarter valued at $92,000. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on AORT shares. Weiss Ratings raised shares of Artivion from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, February 20th. Wall Street Zen cut shares of Artivion from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Stifel Nicolaus set a $55.00 price target on Artivion in a research note on Thursday, March 5th. Needham & Company LLC reissued a “buy” rating and issued a $58.00 price objective on shares of Artivion in a report on Monday, February 2nd. Finally, Canaccord Genuity Group cut their price objective on Artivion from $51.00 to $48.00 and set a “buy” rating on the stock in a research note on Friday, February 13th. Six research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $50.47.

Artivion Stock Performance

Shares of AORT stock opened at $37.45 on Wednesday. The company has a market cap of $1.79 billion, a P/E ratio of 187.26 and a beta of 1.60. The business has a 50 day moving average of $39.81 and a two-hundred day moving average of $42.49. Artivion, Inc. has a 52 week low of $21.97 and a 52 week high of $48.25. The company has a quick ratio of 2.62, a current ratio of 3.53 and a debt-to-equity ratio of 0.49.

Artivion (NYSE:AORT) last announced its quarterly earnings results on Thursday, February 12th. The company reported $0.17 earnings per share for the quarter, topping analysts’ consensus estimates of $0.14 by $0.03. The business had revenue of $118.30 million for the quarter, compared to analysts’ expectations of $116.42 million. Artivion had a return on equity of 7.43% and a net margin of 2.21%.The firm’s revenue was up 19.2% compared to the same quarter last year. As a group, analysts anticipate that Artivion, Inc. will post 0.37 EPS for the current year.

Insider Transactions at Artivion

In related news, EVP Lance A. Berry sold 6,316 shares of Artivion stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $37.78, for a total value of $238,618.48. Following the sale, the executive vice president directly owned 210,827 shares in the company, valued at $7,965,044.06. This trade represents a 2.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Jean F. Holloway sold 8,962 shares of the business’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $38.00, for a total transaction of $340,556.00. Following the transaction, the senior vice president directly owned 185,095 shares of the company’s stock, valued at $7,033,610. The trade was a 4.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 133,043 shares of company stock valued at $4,977,158 over the last three months. 8.10% of the stock is currently owned by company insiders.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.